20/20 Biolabs Faces Nasdaq Delisting Warning and Strikes Standstill with Toxic Financier
AIDX is trading near its 52-week low of $0.491 (9.6% above the low) on light trading volume (0.2× avg).
Summary
20/20 Biolabs disclosed a Nasdaq delisting notice and a temporary standstill with toxic financier Streeterville Capital, buying 120 days of relief from dilutive conversions while racing to fix its sub-$1 stock price.
Key Events · Legal and Risk Events · AIDX
-
Nasdaq Delisting Notice Received
On July 17, 2026, Nasdaq notified the company it is non-compliant with the $1.00 minimum bid price rule after 30 consecutive days below $1. The company has until January 13, 2027, to regain compliance by trading at or above $1 for 10 consecutive business days.
-
Standstill with Toxic Financier
Entered a 120-day standstill with Streeterville Capital, LLC, restricting conversions of Series E Preferred Stock unless the stock trades above 10% of the Nasdaq Minimum Price. The standstill terminates immediately upon any breach or Event of Default.
-
Highly Dilutive Conversion Terms Remain
Series E Preferred Stock converts at the lower of $11.42 or 89% of the lowest 10-day VWAP, with a floor at 20% of the Nasdaq Minimum Price. At current prices, this implies a conversion price near $0.20, enabling massive dilution if the standstill lifts.
-
Fragile Relief — Default Risk
The standstill is contingent on no breaches or Events of Default under the Certificate of Designation. Any default immediately restores Streeterville's right to convert at deeply discounted prices, potentially triggering a death spiral.
Analysis · AIDX · Industrial Applications And Services
A Nasdaq delisting notice landed after 20/20 Biolabs' stock traded below $1 for 30 days, giving the company until January 13, 2027, to regain compliance. At the same time, it entered a 120-day standstill with Streeterville Capital, temporarily blocking conversions of its deeply discounted Series E preferred stock — but only if the stock stays above a floor price. The standstill is fragile: any default or breach terminates it immediately, and the conversion terms remain highly dilutive (89% of the lowest 10-day VWAP, floor at 20% of Nasdaq Minimum Price). With a market cap of just $6.7M and a pending proxy seeking a 900% authorized share increase, this filing underscores acute survival risk — the company is buying time against both delisting and death-spiral dilution.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 42.5% of the 522 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AIDX was trading at $0.54 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $6.7M. The 52-week trading range was $0.49 to $50.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.